Pharmacyte Biotech Inc (OTCMKTS:PMCB) Talks About Pancreatic Cancer Before Phase 2b Human Clinical Trial (SBOTD, USNA)

Pharmacyte Biotech Inc (OTCMKTS:PMCB) is about to start Phase 2b human clinical trial in pancreatic cancer in some time. Before the trial begins, the company has decided to talk about pancreatic cancer to enhance the awareness of people about pancreatic cancer and cutting-edge technology used by the company to treat it.

Cell-In-A-Box Technology

Pharmacyte is known for offering world-class pancreatic cancer treatment with the help of cell-in-a-box technology. Company’s CEO Dr. Gerald W. Crabtree says that unlike other technologies, cell-in-a-box doesn’t use any drug to treat patients. It encapsulates the genetically modified human cells in small protective cocoons or capsules. The total diameter of these capsules’ head is equal to a pin head. The outer shells have some space through which nutrients are sent inside. The waste products of the cells come out through the same holes.

Drug Used By Pharmacyte To Treat Pancreatic Cancer

Pancreatic cancer requires high-end drugs that can heal affected cells in a flesh. As per the reports, Pharmacyte uses ifosfamide to kill the affected cells. Normally, ifosfamide remains inactive. To activate it, Pharmacyte uses cytochrome P450 enzyme system in the human liver. This is how ifosfamide is turned into the cancer-killing form.

The senior management of Pharmacyte intends to start a clinical trial for pancreatic cancer soon to check the efficiency level of its treatments.

Another leading biotech firm Stellar Biotechnologies Inc (OTCMKTS:SBOTD) has also decided to update its shareholders about its listing on NASDAQ marketplace. According to reports, the company is planning to get itself listed on NASDAQ soon. There are some arrangements in company’s corporate governance policies that need to be made before listing. Stellar Biotechnologies will have a meeting with its shareholders on October 29, 2015, to discuss the proposed changed in corporate governance policies.

USANA Health Sciences, Inc. (NYSE:USNA) has been shortlisted as one of the 50 fastest growing companies in Utah state. It’s the 8th straight occasion when USANA has made it to the Utah Business Fast 50 List.

About the Author

Terrel is US Markets Daily’s business news reporter. She joined US Markets Daily after five years as a print reporter.

Leave A Response